Effects of two novel D3-selective compounds, NGB 2904 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl) benzamide], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 2, 2007, Pages 573-582

  Martelle, Jennifer L ^a   Claytor, Renee ^a   Ross, Jason T ^a   Reboussin, Beth A ^a   Newman, Amy Hauck ^b   Nader, Michael A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CJB 090; COCAINE; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; N (4 (4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL)BUTYL) 4 (PYRIDIN 2 YL)BENZAMIDE; N (4 (4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL)BUTYL) 9H FLUORENE 2 CARBOXAMIDE; NGB 2904; QUINPIROLE; UNCLASSIFIED DRUG; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLUORENE DERIVATIVE; HALOPERIDOL; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; COCAINE DEPENDENCE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT; RHESUS MONKEY; YAWNING; ANIMAL; CONDITIONING; DISCRIMINATION LEARNING; DOSE RESPONSE; DRUG EFFECT; MACACA;

ANIMALS; COCAINE; CONDITIONING (PSYCHOLOGY); DISCRIMINATION LEARNING; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORENES; HALOPERIDOL; MACACA MULATTA; MALE; PIPERAZINES; QUINPIROLE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; REINFORCEMENT (PSYCHOLOGY);

EID: 34247282794     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.113571     Document Type: Article

References (40)

1. Ashby CR Jr, Paul M, Gardner EL, Heidebreder CA, and Haganl JJ (2003) Acute administration of the selective D3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse 48:154-156.
2. Beardsley PM, Sokoloff P, Balster RL, and Schwartz JC (2001) The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered. Behav Pharmacol 12:1-11.
3. Caine SB and Koob GF (1993) Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science (Wash DC) 260:1814-1816.
4. Caine SB, Negus SS, and Mello NK (2000) Effects of dopamine D1-like and D2-like agonists on cocaine self-administration in rhesus monkeys: rapid assessment of cocaine dose-effect curves. Psychopharmacology 148:41-51.
5. Carroll FI, Howell LL, and Kuhar MJ (1999) Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J Med Chem 42:2721-2736.
6. Cervo L, Carnovali F, Stark JA, and Mennini T (2003) Cocaine-seeking behavior in response to drug-associated stimuli in rats: involvement of D3 and D2 dopamine receptors. Neuropsychopharmacology 28:1150-1159.
7. Childress AR and O'Brien CP (2000) Dopamine receptor partial agonists could address the duality of cocaine craving. Trends Pharmacol Sci 21:6-9.
8. Claytor R, Lile JA, and Nader MA (2006) The effects of eticlopride and the selective D3-antagonist PNU 99194-A on food- and cocaine-maintained responding in rhesus monkeys. Pharmacol Biochem Behav 83:456-464.
9. Code RA and Tang AH (1991) Yawning produced by dopamine agonists in rhesus monkeys. Eur J Pharmacol 201:235-238.
10. Collins GT, Witkin JM, Newman AH, Svensson KA, Grundt P, Cao J, and Woods JH (2005) Dopamine agonist-induced yawning in rats: a dopamine d3 receptormediated behavior. J Pharmacol Exp Ther 314:310-319.
11. 3 dopamine receptor antagonist SB-277011-A. Neuropsychopharmacology 28:329-338.
12. Gal K and Gyertyan I (2006) Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats. Drug Alcohol Depend 81:63-70.
13. Gilbert JG, Newman AH, Gardner EL, Ashby CR, Heidbreder CA, Pak AC, Peng X, and Xi Z (2005) Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse 57:17-28.
14. Gorelick DA, Gardner EL, and Xi Z-X (2004) Agents in development for the management of cocaine abuse. Drugs 64:1547-1573.
15. Grundt P, Carlsson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, and Newman AH (2005) Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl} arylcaroxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem 48:839-848.
16. Jennrich RI and Schluchter MD (1986) Unbalanced repeated-measures models with structured covariance matrices. Biometrics 42:805-820.
17. Kleven MS, Anthony EW, and Woolverton WL (1990) Pharmacological characterization of the discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 254:312-317.
18. 3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 49:231-252.
19. Lile JA, Wang Z, Woolverton WL, France JE, Gregg TC, Davies HM, and Nader MA (2003) The reinforcing efficacy of psychostimulants in rhesus monkeys: the role of pharmacokinetics and pharmacodynamics. J Pharmacol Exp Ther 307:356-366.
20. Mello NK and Negus SS (1996) Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neurpsychopharmacology 14:375-424.
21. Nader MA, Sinnott RS, Mach RH, and Morgan D (2002) Cocaine- and foodmaintained responding under a multiple schedule in rhesus monkeys: environmental context and the effects of a dopamine antagonist. Psychopharmacology 163:292-301.
22. Negus SS (2006) Some implications of receptor theory for in vivo assessments of agonists, antagonists and inverse agonists. Biochem Pharmacol 71:1663-1670.
23. Newman AH, Cao J, Bennett CJ, Robarge MJ, Freeman RA, and Luedtke RR (2003) N-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl}arylcarboxamides as novel dopamine D3 receptor antagonists. Bioorg Med Chem Lett 13:2179-2183.
24. Newman AH, Grundt P, and Nader MA (2005) Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem 48:3664-3679.
25. NIDA (2004) 2003 National Survey on Drug Use and Health (NSDUH), U.S. Department of Health and Human Services, National Institute on Drug Abuse, Rockville, MD.
26. O'Brien CP (2005) Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry 162:1423-1431.
27. 3 receptor agonist. Nature (Lond) 400:371-375.
28. Platt DM, Rowlett JK, and Spealman RD (2002) Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology 163:265-282.
29. Pulvirenti L and Koob GF (1994) Dopamine receptor agonists, partial agonists and psychostimulant addiction. Trends Pharmacol Sci 15:374-379.
30. Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC, et al. (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 294:1154-1165.
31. Ritz MC, Lamb RJ, Goldberg SR, and Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science (Wash DC) 237:1219-1223.
32. 3) as a target for neuroleptics. Nature (Lond) 347:146-151.
33. 3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 16:6100-6106.
34. Substance Abuse and Mental Health Services Administration, United States Department of Health and Human Services, Substance Abuse and Mental Health Services Administration (SAMHSA) Office of Applied Studies (2004) Results from the 2003 National Survey on Drug Use and Health, NSDUH Series H-25, Department of Health and Human Services Publication No. (SMA) 04-3964, U.S. Department of Health and Human Services, Rockville, MD.
35. Vocci FJ, Acri J, and Elkashef A (2005) Medication development for addictive disorders: the state of the science. Am J Psychiatry 162:1432-1440.
36. Vorel SR, Ashby CR, Paul M, Liu X, Hayes R, Hagan JJ, Middlemiss DN, Stemp G, and Gardner EL (2002) Dopamine D3 receptor antagonism inhibits cocaineseeking and cocaine-enhanced brain reward in rats. J Neurosci 22:9595-9603.
37. World Health Organization (2004) Neuroscience of Psychoactive Substance Use and Dependence, World Health Organization, Geneva, Switzerland.
38. Xi ZX, Gilbert JG, Pak AC, Ashby CR, Heidbreder CA, and Gardner EL (2005) Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats. Eur J Neurosci 21:3427-3438.
39. Xi ZX, Newman AH, Gilbert JG, Pak AC, Peng XQ, Ashby CR Jr, Gitajn L, and Gardner EL (2006) The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 31:1393-1405.
40. Yuan J, Chen X, Brodbeck R, Primus R, Braun J, Wasley JWF, and Thurkauf A (1998) NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists. Bioorg Med Chem Lett 8:2715-2718.